Trials / Unknown
UnknownNCT01470495
Combined Treatment of RFA and Sorafenib on Recurrent HCC
Radiofrequency Ablation Plus Sorafenib Administration in Early Recurrent Hepatocellular Carcinoma: a Prospective Multicenter Cohort Trial (Repeat) Tumors for BCLC B Stage HCC Undergone Curative Hepatectomy
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 430 (estimated)
- Sponsor
- Southwest Hospital, China · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
RFA is a routaine treatment of recurrent HCC. Recently Sorafenib was reported to be a promising drug to treat late stage HCC. But few studies were related with its effectiveness on recurrent HCC. So the investigators hypothesized that combined RFA and Sorafenib might reduce the frequency of recurrence and improve the overall survival and disease free survial.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | RFA + Sorafenib | combined RFA and Sorafenib to treat recurrent HCC |
| OTHER | RFA | treat Recurrent HCC with RFA |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2011-11-11
- Last updated
- 2017-03-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01470495. Inclusion in this directory is not an endorsement.